Skip to main content
Erschienen in: Quality of Life Research 10/2013

01.12.2013

Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials

verfasst von: Donald W. Robinson Jr., Ning Zhao, Fitzroy Dawkins, Ming Qi, Dennis Revicki

Erschienen in: Quality of Life Research | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare pain assessment questionnaires commonly used in advanced prostate cancer trials and to determine the psychometric characteristics and longitudinal relationships by contrasting questionnaire data from two international phase 2 trials.

Methods

Scores from the Present Pain Intensity (PPI) question of the McGill Pain Questionnaire, the pain intensity scale of the Brief Pain Inventory (BPI), and the Functional Assessment of Cancer Therapy-Prostate (FACT-P) were analyzed using Pearson correlation, intraclass correlation coefficient, and Cronbach’s α, respectively. Concordance was evaluated with Cohen’s kappa coefficient and McNemar test at baseline (n = 224) and two subsequent observations.

Results

PPI and FACT-P scores were associated with the BPI score at baseline for Trials 1 and 2: PPI r = 0.66 and 0.80, respectively (P < 0.001); FACT-P (pain scale) r = −0.76 and −0.82, respectively (P < 0.001). However, concordance analysis revealed that the BPI identified pain (score > 0) at higher rates than the PPI: at baseline, BPI: 89 % (64/72) and 77 % (95/124), PPI: 68 % (49/72) and 64 % (79/124) [Trials 1 and 2, respectively; McNemar test (P < 0.001) for both studies]. The FACT-P pain scale identified pain similarly to the BPI pain intensity scale; longitudinal analysis produced comparable findings. All pain scales met standard psychometric acceptability criteria, but the BPI and FACT-P performed better than the PPI.

Conclusions

Data suggest the BPI pain intensity and FACT-P pain scales are better than the PPI question at capturing the pain experience among patients with advanced prostate cancer. Additional comparative research is needed in larger population samples.
Literatur
1.
Zurück zum Zitat Lee, D. J., Cha, E. K., Dubin, J. M., Beltran, H., Chromecki, T. F., Fajkovic, H., et al. (2012). Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU International, 109(7), 968–985.PubMedCrossRef Lee, D. J., Cha, E. K., Dubin, J. M., Beltran, H., Chromecki, T. F., Fajkovic, H., et al. (2012). Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU International, 109(7), 968–985.PubMedCrossRef
2.
Zurück zum Zitat de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376(9747), 1147–1154.PubMedCrossRef de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376(9747), 1147–1154.PubMedCrossRef
3.
Zurück zum Zitat de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), 1995–2005.PubMedCrossRef de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), 1995–2005.PubMedCrossRef
4.
Zurück zum Zitat Parker, C., Heinrich, D., O’Sullivan, J. M., Fossá, S. D., Chodacki, A., Demkow, T., et al. (2011). Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): A phase III randomized trial (ALSYMPCA). [abstract 1LBA]. European Journal of Cancer, 47(suppl 2), 3.CrossRef Parker, C., Heinrich, D., O’Sullivan, J. M., Fossá, S. D., Chodacki, A., Demkow, T., et al. (2011). Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): A phase III randomized trial (ALSYMPCA). [abstract 1LBA]. European Journal of Cancer, 47(suppl 2), 3.CrossRef
5.
Zurück zum Zitat Mukherji, D., Pezaro, C. J., & De-Bono, J. S. (2012). MDV3100 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 21(2), 227–233.PubMedCrossRef Mukherji, D., Pezaro, C. J., & De-Bono, J. S. (2012). MDV3100 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 21(2), 227–233.PubMedCrossRef
6.
Zurück zum Zitat Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., et al. (2012). Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer, 48(1), 85–93.PubMedCrossRef Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., et al. (2012). Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer, 48(1), 85–93.PubMedCrossRef
7.
Zurück zum Zitat Chu, F. M., Picus, J., Fracasso, P. M., Dreicer, R., Lang, Z., & Foster, B. (2011). A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Investigational New Drugs, 29(4), 674–679.PubMedCrossRef Chu, F. M., Picus, J., Fracasso, P. M., Dreicer, R., Lang, Z., & Foster, B. (2011). A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Investigational New Drugs, 29(4), 674–679.PubMedCrossRef
8.
Zurück zum Zitat Atkinson, T. M., Mendoza, T. R., Sit, L., Passik, S., Scher, H. I., Cleeland, C., et al. (2010). The Brief Pain Inventory and its “pain at its worst in the last 24 hours” item: Clinical trial endpoint considerations. Pain Medicine, 11(3), 337–346.PubMedCrossRef Atkinson, T. M., Mendoza, T. R., Sit, L., Passik, S., Scher, H. I., Cleeland, C., et al. (2010). The Brief Pain Inventory and its “pain at its worst in the last 24 hours” item: Clinical trial endpoint considerations. Pain Medicine, 11(3), 337–346.PubMedCrossRef
9.
Zurück zum Zitat Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–928.PubMedCrossRef Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–928.PubMedCrossRef
10.
Zurück zum Zitat Jensen, M. P. (2003). The validity and reliability of pain measures in adults with cancer. Journal of Pain, 4(1), 2–21.PubMedCrossRef Jensen, M. P. (2003). The validity and reliability of pain measures in adults with cancer. Journal of Pain, 4(1), 2–21.PubMedCrossRef
11.
Zurück zum Zitat Melzack, R. (1975). The McGill Pain Questionnaire: Major properties and scoring methods. Pain, 1(3), 277–299.PubMedCrossRef Melzack, R. (1975). The McGill Pain Questionnaire: Major properties and scoring methods. Pain, 1(3), 277–299.PubMedCrossRef
12.
Zurück zum Zitat Rosenfeld, B., Roth, A. J., Gandhi, S., & Penson, D. (2004). Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psycho-oncology, 13(11), 800–807.PubMedCrossRef Rosenfeld, B., Roth, A. J., Gandhi, S., & Penson, D. (2004). Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psycho-oncology, 13(11), 800–807.PubMedCrossRef
13.
Zurück zum Zitat Melzack, R., & Katz, J. (2001). The McGill Pain Questionnaire: Appraisal and current status. In D. C. Turk & R. Melzack (Eds.), Handbook of pain assessment (2nd ed., pp. 35–52). New York: Guilford Press. Melzack, R., & Katz, J. (2001). The McGill Pain Questionnaire: Appraisal and current status. In D. C. Turk & R. Melzack (Eds.), Handbook of pain assessment (2nd ed., pp. 35–52). New York: Guilford Press.
14.
Zurück zum Zitat Cella, D., Nichol, M. B., Eton, D., Nelson, J. B., & Mulani, P. (2009). Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy–prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health, 12(1), 124–129.PubMedCrossRef Cella, D., Nichol, M. B., Eton, D., Nelson, J. B., & Mulani, P. (2009). Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy–prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health, 12(1), 124–129.PubMedCrossRef
15.
Zurück zum Zitat Webster, K., Cella, D., & Yost, K. (2003). The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.PubMedCrossRef Webster, K., Cella, D., & Yost, K. (2003). The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.PubMedCrossRef
16.
Zurück zum Zitat Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502–1512.PubMedCrossRef Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502–1512.PubMedCrossRef
17.
Zurück zum Zitat Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., et al. (2008). Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. Journal of Clinical Oncology, 26(15), 2544–2549.PubMedCrossRef Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., et al. (2008). Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. Journal of Clinical Oncology, 26(15), 2544–2549.PubMedCrossRef
18.
Zurück zum Zitat Jensen, M. P. (2008). Pain assessment in clinical trials. In H. M. Wittink & D. B. Carr (Eds.), Pain management: Evidence, outcomes, and quality of life: A sourcebook (pp. 57–88). Philadelphia: Elsevier. Jensen, M. P. (2008). Pain assessment in clinical trials. In H. M. Wittink & D. B. Carr (Eds.), Pain management: Evidence, outcomes, and quality of life: A sourcebook (pp. 57–88). Philadelphia: Elsevier.
19.
Zurück zum Zitat Ferreira-Valente, M. A., Pais-Ribeiro, J. L., & Jensen, M. P. (2011). Validity of four pain intensity rating scales. Pain, 152(10), 2399–2404.PubMedCrossRef Ferreira-Valente, M. A., Pais-Ribeiro, J. L., & Jensen, M. P. (2011). Validity of four pain intensity rating scales. Pain, 152(10), 2399–2404.PubMedCrossRef
20.
Zurück zum Zitat Cleeland, C. S., O’Mara, A., Zagari, M., & Baas, C. (2011). Integrating pain metrics into oncology clinical trials. Clinical Cancer Research, 17(21), 6646–6650.PubMedCrossRef Cleeland, C. S., O’Mara, A., Zagari, M., & Baas, C. (2011). Integrating pain metrics into oncology clinical trials. Clinical Cancer Research, 17(21), 6646–6650.PubMedCrossRef
21.
Zurück zum Zitat Basch, E. M., Sit, L., Fruscione, M., Burke, L., Kane, R., George, D., et al. (2009). Pain and analgesic use in men with metastatic prostate cancer [abstract]. Journal of Clinical Oncology, 27(Suppl, 15S), e20515. Basch, E. M., Sit, L., Fruscione, M., Burke, L., Kane, R., George, D., et al. (2009). Pain and analgesic use in men with metastatic prostate cancer [abstract]. Journal of Clinical Oncology, 27(Suppl, 15S), e20515.
22.
Zurück zum Zitat Sandblom, G., Carlsson, P., Sigsjö, P., & Varenhorst, E. (2001). Pain and health-related quality of life in a geographically defined population of men with prostate cancer. British Journal of Cancer, 85(4), 497–503.PubMedCrossRef Sandblom, G., Carlsson, P., Sigsjö, P., & Varenhorst, E. (2001). Pain and health-related quality of life in a geographically defined population of men with prostate cancer. British Journal of Cancer, 85(4), 497–503.PubMedCrossRef
23.
Zurück zum Zitat Sullivan, P. W., Mulani, P. M., Fishman, M., & Sleep, D. (2007). Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 16(4), 571–575.PubMedCrossRef Sullivan, P. W., Mulani, P. M., Fishman, M., & Sleep, D. (2007). Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 16(4), 571–575.PubMedCrossRef
24.
Zurück zum Zitat Berthold, D. R., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M., & Tannock, A. I. (2008). Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clinical Cancer Research, 14(9), 2763–2767.PubMedCrossRef Berthold, D. R., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M., & Tannock, A. I. (2008). Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clinical Cancer Research, 14(9), 2763–2767.PubMedCrossRef
25.
Zurück zum Zitat Collette, L., van Andel, G., Bottomley, A., Oosterhof, G. O., Albrecht, W., de Reijke, T. M., et al. (2004). Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Journal of Clinical Oncology, 22(19), 3877–3885.PubMedCrossRef Collette, L., van Andel, G., Bottomley, A., Oosterhof, G. O., Albrecht, W., de Reijke, T. M., et al. (2004). Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Journal of Clinical Oncology, 22(19), 3877–3885.PubMedCrossRef
26.
Zurück zum Zitat Sullivan, P. W., Nelson, J. B., Mulani, P. M., & Sleep, D. (2006). Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 15(8), 1297–1306.PubMedCrossRef Sullivan, P. W., Nelson, J. B., Mulani, P. M., & Sleep, D. (2006). Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 15(8), 1297–1306.PubMedCrossRef
27.
Zurück zum Zitat Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., et al. (2007). Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology, 25(25), 3965–3970.PubMedCrossRef Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., et al. (2007). Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology, 25(25), 3965–3970.PubMedCrossRef
28.
Zurück zum Zitat Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 26(7), 1148–1159.PubMedCrossRef Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 26(7), 1148–1159.PubMedCrossRef
29.
Zurück zum Zitat Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007). A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clinical Cancer Research, 13(21), 6396–6403.PubMedCrossRef Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007). A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clinical Cancer Research, 13(21), 6396–6403.PubMedCrossRef
30.
Zurück zum Zitat Fayers, P. M., Hopwood, P., Harvey, A., Girling, D. J., Machin, D., & Stephens, R. (1997). Quality of life assessment in clinical trials–guidelines and a checklist for protocol writers: The U.K. Medical Research Council experience. MRC Cancer Trials Office. European Journal of Cancer, 33(1), 20–28.PubMedCrossRef Fayers, P. M., Hopwood, P., Harvey, A., Girling, D. J., Machin, D., & Stephens, R. (1997). Quality of life assessment in clinical trials–guidelines and a checklist for protocol writers: The U.K. Medical Research Council experience. MRC Cancer Trials Office. European Journal of Cancer, 33(1), 20–28.PubMedCrossRef
31.
Zurück zum Zitat Hahn, E. A., Webster, K. A., Cella, D., & Fairclough, D. L. (1998). Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: Problems and solutions. Statistics in Medicine, 17(5–7), 547–559.PubMedCrossRef Hahn, E. A., Webster, K. A., Cella, D., & Fairclough, D. L. (1998). Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: Problems and solutions. Statistics in Medicine, 17(5–7), 547–559.PubMedCrossRef
32.
Zurück zum Zitat Hopwood, P., Harvey, A., Davies, J., Stephens, R. J., Girling, D. J., Gibson, D., et al. (1998). Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. European Journal of Cancer, 34(1), 49–57.PubMedCrossRef Hopwood, P., Harvey, A., Davies, J., Stephens, R. J., Girling, D. J., Gibson, D., et al. (1998). Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. European Journal of Cancer, 34(1), 49–57.PubMedCrossRef
33.
Zurück zum Zitat Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86(2), 420–428.PubMedCrossRef Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86(2), 420–428.PubMedCrossRef
34.
Zurück zum Zitat Deyo, R. A., Diehr, P., & Patrick, D. L. (1991). Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials, 12(4 Suppl), 142S–158S.PubMedCrossRef Deyo, R. A., Diehr, P., & Patrick, D. L. (1991). Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials, 12(4 Suppl), 142S–158S.PubMedCrossRef
35.
Zurück zum Zitat Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials: Methods and practice (2nd ed., pp. 25–39). Oxford: Oxford University Press. Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials: Methods and practice (2nd ed., pp. 25–39). Oxford: Oxford University Press.
36.
Zurück zum Zitat Yuen, K. K., Shelley, M., Sze, W. M., Wilt, T. J., & Mason, M. (2006). Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews (4), CD006250. Yuen, K. K., Shelley, M., Sze, W. M., Wilt, T. J., & Mason, M. (2006). Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews (4), CD006250.
37.
Zurück zum Zitat Wong, R. & Wiffen, P. J. (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Systematic Reviews (2), CD002068. Wong, R. & Wiffen, P. J. (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Systematic Reviews (2), CD002068.
38.
Zurück zum Zitat Mercadante, S., & Fulfaro, F. (2005). World Health Organization guidelines for cancer pain: A reappraisal. Annals of Oncology, 16(Suppl 4), iv132–iv135.PubMed Mercadante, S., & Fulfaro, F. (2005). World Health Organization guidelines for cancer pain: A reappraisal. Annals of Oncology, 16(Suppl 4), iv132–iv135.PubMed
39.
Zurück zum Zitat Bader, P., Echtle, D., Fonteyne, V., Livadas, K., De Meerleer, G., Paez Borda, A., et al. (2012). Prostate cancer pain management: EAU guidelines on pain management. World Journal of Urology, 30(5), 677–686.PubMedCrossRef Bader, P., Echtle, D., Fonteyne, V., Livadas, K., De Meerleer, G., Paez Borda, A., et al. (2012). Prostate cancer pain management: EAU guidelines on pain management. World Journal of Urology, 30(5), 677–686.PubMedCrossRef
40.
Zurück zum Zitat Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., et al. (2003). Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain, 106(3), 337–345.PubMedCrossRef Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., et al. (2003). Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain, 106(3), 337–345.PubMedCrossRef
41.
Zurück zum Zitat Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., et al. (2008). Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain, 9(2), 105–121.PubMedCrossRef Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., et al. (2008). Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain, 9(2), 105–121.PubMedCrossRef
42.
Zurück zum Zitat Schulz, K. F., & Grimes, D. A. (2005). Multiplicity in randomised trials I: Endpoints and treatments. Lancet, 365(9470), 1591–1595.PubMedCrossRef Schulz, K. F., & Grimes, D. A. (2005). Multiplicity in randomised trials I: Endpoints and treatments. Lancet, 365(9470), 1591–1595.PubMedCrossRef
43.
Zurück zum Zitat Turk, D. C., Dworkin, R. H., McDermott, M. P., Bellamy, N., Burke, L. B., Chandler, J. M., et al. (2008). Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on methods, measurement, and pain assessment in clinical trials. Pain, 139(3), 485–493.PubMedCrossRef Turk, D. C., Dworkin, R. H., McDermott, M. P., Bellamy, N., Burke, L. B., Chandler, J. M., et al. (2008). Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on methods, measurement, and pain assessment in clinical trials. Pain, 139(3), 485–493.PubMedCrossRef
44.
Zurück zum Zitat Ahles, T. A., Herndon, J. E, 2nd, Small, E. J., Vogelzang, N. J., Kornblith, A. B., Ratain, M. J., et al. (2004). Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: Results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer, 101(10), 2202–2208.PubMedCrossRef Ahles, T. A., Herndon, J. E, 2nd, Small, E. J., Vogelzang, N. J., Kornblith, A. B., Ratain, M. J., et al. (2004). Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: Results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer, 101(10), 2202–2208.PubMedCrossRef
45.
Zurück zum Zitat Berry, D. L., Moinpour, C. M., Jiang, C. S., Ankerst, D. P., Petrylak, D. P., Vinson, L. V., et al. (2006). Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of Clinical Oncology, 24(18), 2828–2835.PubMedCrossRef Berry, D. L., Moinpour, C. M., Jiang, C. S., Ankerst, D. P., Petrylak, D. P., Vinson, L. V., et al. (2006). Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of Clinical Oncology, 24(18), 2828–2835.PubMedCrossRef
46.
Zurück zum Zitat Oh, W. K., Manola, J., Babcic, V., Harnam, N., & Kantoff, P. W. (2006). Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology, 67(6), 1235–1240.PubMedCrossRef Oh, W. K., Manola, J., Babcic, V., Harnam, N., & Kantoff, P. W. (2006). Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology, 67(6), 1235–1240.PubMedCrossRef
47.
Zurück zum Zitat Wu, E. Q., Mulani, P., Farrell, M. H., & Sleep, D. (2007). Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value in Health, 10(5), 408–414.PubMedCrossRef Wu, E. Q., Mulani, P., Farrell, M. H., & Sleep, D. (2007). Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value in Health, 10(5), 408–414.PubMedCrossRef
48.
Zurück zum Zitat Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., et al. (2005). The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Annals of Oncology, 16(4), 579–584.PubMedCrossRef Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., et al. (2005). The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Annals of Oncology, 16(4), 579–584.PubMedCrossRef
49.
Zurück zum Zitat Gater, A., Abetz-Webb, L., Battersby, C., Parasuraman, B., McIntosh, S., Nathan, F., et al. (2011). Pain in castration-resistant prostate cancer with bone metastases: A qualitative study. Health and Quality of Life Outcomes, 9(88). Gater, A., Abetz-Webb, L., Battersby, C., Parasuraman, B., McIntosh, S., Nathan, F., et al. (2011). Pain in castration-resistant prostate cancer with bone metastases: A qualitative study. Health and Quality of Life Outcomes, 9(88).
50.
Zurück zum Zitat Farrar, J. T. (2010). Advances in clinical research methodology for pain clinical trials. Nature Medicine, 16(11), 1284–1293.PubMed Farrar, J. T. (2010). Advances in clinical research methodology for pain clinical trials. Nature Medicine, 16(11), 1284–1293.PubMed
Metadaten
Titel
Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials
verfasst von
Donald W. Robinson Jr.
Ning Zhao
Fitzroy Dawkins
Ming Qi
Dennis Revicki
Publikationsdatum
01.12.2013
Verlag
Springer Netherlands
Erschienen in
Quality of Life Research / Ausgabe 10/2013
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-013-0411-z

Weitere Artikel der Ausgabe 10/2013

Quality of Life Research 10/2013 Zur Ausgabe